1. Home
  2. ACHL vs ZDGE Comparison

ACHL vs ZDGE Comparison

Compare ACHL & ZDGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACHL
  • ZDGE
  • Stock Information
  • Founded
  • ACHL 2016
  • ZDGE 2008
  • Country
  • ACHL United Kingdom
  • ZDGE United States
  • Employees
  • ACHL N/A
  • ZDGE N/A
  • Industry
  • ACHL Biotechnology: Biological Products (No Diagnostic Substances)
  • ZDGE Computer Software: Prepackaged Software
  • Sector
  • ACHL Health Care
  • ZDGE Technology
  • Exchange
  • ACHL Nasdaq
  • ZDGE Nasdaq
  • Market Cap
  • ACHL 46.0M
  • ZDGE 40.3M
  • IPO Year
  • ACHL 2021
  • ZDGE N/A
  • Fundamental
  • Price
  • ACHL $1.38
  • ZDGE $2.65
  • Analyst Decision
  • ACHL Buy
  • ZDGE
  • Analyst Count
  • ACHL 2
  • ZDGE 0
  • Target Price
  • ACHL $4.00
  • ZDGE N/A
  • AVG Volume (30 Days)
  • ACHL 1.9M
  • ZDGE 58.5K
  • Earning Date
  • ACHL 04-03-2025
  • ZDGE 03-14-2025
  • Dividend Yield
  • ACHL N/A
  • ZDGE N/A
  • EPS Growth
  • ACHL N/A
  • ZDGE N/A
  • EPS
  • ACHL N/A
  • ZDGE N/A
  • Revenue
  • ACHL N/A
  • ZDGE $30,204,000.00
  • Revenue This Year
  • ACHL N/A
  • ZDGE $0.34
  • Revenue Next Year
  • ACHL N/A
  • ZDGE $6.35
  • P/E Ratio
  • ACHL N/A
  • ZDGE N/A
  • Revenue Growth
  • ACHL N/A
  • ZDGE 10.15
  • 52 Week Low
  • ACHL $0.63
  • ZDGE $1.93
  • 52 Week High
  • ACHL $1.76
  • ZDGE $4.69
  • Technical
  • Relative Strength Index (RSI)
  • ACHL 72.41
  • ZDGE 44.69
  • Support Level
  • ACHL $1.10
  • ZDGE $2.65
  • Resistance Level
  • ACHL $1.41
  • ZDGE $2.89
  • Average True Range (ATR)
  • ACHL 0.02
  • ZDGE 0.16
  • MACD
  • ACHL 0.00
  • ZDGE -0.02
  • Stochastic Oscillator
  • ACHL 90.48
  • ZDGE 30.61

About ACHL Achilles Therapeutics plc

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

About ZDGE Zedge Inc. Class B

Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.

Share on Social Networks: